A randomized, double-blind, dosecomparison study of weekly interferon B-1a in relapsing MS

A randomized, double-blind, dosecomparison study of weekly interferon B-1a in relapsing MS2018-01-17T17:03:31-05:00

Minocycline Reduces Gadolinium-Enhancing Magnetic Resonance Imaging Lesions in Multiple Sclerosis

Minocycline Reduces Gadolinium-Enhancing Magnetic Resonance Imaging Lesions in Multiple Sclerosis2018-01-17T17:03:25-05:00

Lack of evidence for use of glatiramer acetate in multiple sclerosis

Lack of evidence for use of glatiramer acetate in multiple sclerosis2018-01-17T17:03:25-05:00

The coming of age for antigen-specific therapy of multiple sclerosis

The coming of age for antigen-specific therapy of multiple sclerosis2018-01-17T17:03:13-05:00

Intramuscular Interferon Beta-1A Therapy Initiated During A First Demyelinating Event In Multiple Sclerosis

Intramuscular Interferon Beta-1A Therapy Initiated During A First Demyelinating Event In Multiple Sclerosis2018-01-17T17:03:13-05:00

Multiple Sclerosis: Update on Treatment

Multiple Sclerosis: Update on Treatment2018-01-17T17:03:13-05:00

Current Therapy of Multiple Sclerosis

Current Therapy of Multiple Sclerosis2018-01-17T17:03:07-05:00

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes2018-01-17T17:03:07-05:00

Needed in MS Evidence, not EVIDENCE

Needed in MS Evidence, not EVIDENCE2018-01-17T17:03:01-05:00

Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment

Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment2018-01-17T17:03:01-05:00